Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07163364 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type)

Name: A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type) — clinical trial record (NCT07163364)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorCSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Started2025-08-31

View on ClinicalTrials.gov ↗

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

42 trials monitored

See 1 trial at risk

This study is a Single-Center, Single-Arm, open-label, Phase III clinical study to evaluate the efficacy, safety characteristics of Hydroxocobalamin Chloride Injection (20 mg/mL) for Maintenance Therapy in participants with Methylmalonic Acidemia (MMA) with Elevated Homocysteine (Cobalamin C Deficiency).

Trial Details

NCT Number	NCT07163364
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	Methylmalonic Acidemia (MMA)
Enrollment	20 participants
Start Date	2025-08-31
Primary Completion	2026-10-08 (estimated)
Study Completion	2027-04-28 (estimated)
Updated on ClinicalTrials.gov	2025-09-09